{
    "nctId": "NCT00777530",
    "briefTitle": "Study Evaluating Ascending Single-Dose Of Bosutinib Administered With Multiple Doses Of Ketoconazole To Healthy Subjects",
    "officialTitle": "Ascending Single-Dose Of The Safety, Tolerability, And Pharmacokinetics Of Bosutinib Administered Orally With Multiple Doses Of Ketoconazole To Healthy Adult Subjects.",
    "overallStatus": "COMPLETED",
    "conditions": "Breast Cancer, Tumors, Leukemia",
    "studyType": "INTERVENTIONAL",
    "phase": "PHASE1",
    "allocation": "RANDOMIZED",
    "primaryPurpose": "N/A",
    "enrollmentCount": 48,
    "primaryOutcomeMeasure": "Safety based on adverse events monitoring, physical examinations, vital sign evaluations, 12-lead ECGs and routine laboratory tests.",
    "eligibilityCriteria": "Inclusion criteria:\n\n1. Men or women of nonchildbearing potential (WONCBP) aged 18 to 50 years inclusive on study day 1. WONCBP may be included if they are either surgically sterile (hysterectomy and/or oophorectomy) or postmenopausal for \u2265 1 year (with follicle-stimulating hormone \\[FSH\\] \u2265 38 mIU/mL) and must have a negative serum pregnancy test result before administration of test article.\n2. Body mass index (BMI) in the range of 18.0 to 30.0 kg/m2 and body weight \u2265 50 kg.\n3. Healthy as determined by the investigator on the basis of screening evaluations.\n\nExclusion criteria:\n\n1. Family history QT prolongation, syncope, seizure, or unexplained cardiac related death.\n2. Presence or history of any disorder that may prevent the successful completion of the study.\n3. Any significant cardiovascular, hepatic, renal, respiratory, gastrointestinal, endocrine, immunologic, dermatologic, hematologic, neurologic, or psychiatric disease.",
    "sex": "ALL",
    "minimumAge": "18 Years",
    "stdAges": "ADULT"
}